Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea

Tien-Yu Chen1,2, Chi-Hsiang Chung3,4,5, Hsin-An Chang1,6, Yu-Chen Kao1,7, Shan-Yueh Chang8,9, Terry B. J. Kuo1,10, Cheryl C. H. Yang2, Wu-Chien Chien1,4,11,12 & Nian-Sheng Tzeng1,6,12*

One recent study showed that atomoxetine-oxybutynin combination (AOC) use is effective in reducing obstructive sleep apnea (OSA) severity. We used a nationwide database to examine the association between AOC use and the risk of OSA incidence. This retrospective cohort study used Taiwan’s National Health Insurance Research Database between the years 2000 and 2015. The patients who used atomoxetine or oxybutynin were included as an exposed cohort. The exposed and unexposed groups were selected in a ratio of 1:3 with sex, age, and index year matching. We used the multivariate Cox proportional regression model to evaluate the association between AOC use and the risk of an incident diagnosis of OSA. The incidence rates of OSA in the exposed cohort (N = 8940) and the unexposed cohort (N = 26,820), were 21.92 and 22.93 per 100,000 person-years, respectively. The adjusted hazard ratio of oxybutynin use only and AOC with a treatment duration of ≥ 366 days were 0.307 (95% CI 0.204–0.995, \( P = 0.045 \)) and 0.299 (95% CI 0.102–0.933, \( P = 0.002 \)), respectively. Long-term atomoxetine-oxybutynin combination therapy may be beneficial to reduce the risk of obstructive sleep apnea. Further studies to examine these mechanisms are warranted.

Obstructive sleep apnea (OSA) is a common disorder characterized by episodic upper airway obstruction during sleep1. The symptoms and signs of OSA include sleep fragmentation, hypoxia, hypercapnia, and increased sympathetic activity during sleep6. Increasing evidence has indicated that OSA is significantly associated with the risk of motor vehicle accidents3, cardiovascular diseases4, cerebrovascular morbidities5–7, and metabolic syndrome8. The treatment is considered for patients with apnea–hypopnea index (AHI) ≥ 15 per hour and those with OSA-related symptoms, such as daytime sleepiness and impaired cognitive function9.

Several treatment options are available for OSA. Positive airway pressure (PAP) therapy is efficacious and can improve both subjective and objective sleepiness and daytime functions10. However, poor adherence to long-term PAP therapy is a limitation11. The oral appliance therapy could be used for mild-to-moderate OSA patients who are unable to use PAP; however, long-term use of the appliance may cause dental side effects12.

1Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan. 2Institute of Brain Science, National Yang Ming Chiao Tung University, Taipei 112, Taiwan. 3Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. 4School of Public Health, National Defense Medical Center, Taipei, Taiwan. 5Taiwanese Injury Prevention and Safety Promotion Association, Taipei, Taiwan. 6Student Counseling Center, National Defense Medical Center, Taipei, Taiwan. 7Department of Psychiatry, Tri-Service General Hospital, Song-Shan Branch, School of Medicine, National Defense Medical Center, Taipei, Taiwan. 8Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan. 9Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan. 10Clinical Research Center, Taoyuan Psychiatric Center, Ministry of Health and Welfare, Taoyuan, Taiwan. 11Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan. 12These authors contributed equally: Wu-Chien Chien and Nian-Sheng Tzeng. *email: chienwu@mail.ndmctsgh.edu.tw; pierrens@mail.ndmctsgh.edu.tw
Surgical interventions like uvulopharyngopalatoplasty and hypoglossal nerve stimulation may be helpful for patients with favorable anatomy\textsuperscript{13,14}. The evidence of pharmacologic intervention for the treatment of OSA is still sparse. A systematic review found some drugs like acetazolamide, tramazoline, iriglutide, spirolactone/furosemide, dronabinol, zonisamide, phentermine, spirolactone, and ondansetron/fluoxetine may have benefits on reducing AHI compared to placebo. However, most of the selected trials were not adequately evaluated\textsuperscript{15}.

One recent well-designed trial has shown that the use of atomoxetine 80 mg and oxybutynin 5 mg, atomoxetine-oxybutynin combination (AOC) treatment, but not monotherapy, appear to be immediately effective in lowering the AHI in patients with OSA by increasing the genioglossus responsiveness\textsuperscript{16}. To examine this, we used a nationwide population-based registry dataset to evaluate the relationship between the use of atomoxetine/ oxybutynin and the risk of incident diagnosis of OSA.

Results

Sample characteristics. Table 1 shows the baseline characteristics of sex, age, comorbidities, urbanization, area of residence, monthly insured premiums of the participants in the exposed and unexposed cohort. When compared to the unexposed cohort, the participants in the exposed cohort tended to have higher rates of attention-deficit hyperactivity disorder (ADHD), overactive bladder syndrome (OAB), diabetes mellitus (DM), hypertension, and Charlson Comorbidity Index, revised (CCI-R) scored 0 and 3, and lower rates of hyperlipidemia and coronary artery disease (CAD). The participants in the exposed cohort tended to have slightly higher rates of the monthly insured premiums of the NT$ ≥ 35,000, and 18,000–34,999. The participants in the exposed cohort tended to have higher rates of living in the north and east of Taiwan, in urbanization level 1 and 2 areas, and searching medical help from the medical centers and regional hospitals than the controls.

Kaplan–Meier model for the cumulative risk of OSA. There was no significant difference between the cumulative incident diagnosis of OSA in the participants in exposed and unexposed cohorts (P-value of the log-rank test = 0.336).

Factors contributing to OSA. Table 2 depicts that the Cox regression analysis of the factors contributing to OSA. The crude hazard ratio (HR) for patients with atomoxetine or oxybutynin use and the incident diagnosis of OSA was 0.896 (95% CI 0.681–1.323, \( P = 0.242 \)). After adjusting for gender, age, marital status, educational years, monthly income, ADHD, OAB, DM, hyperlipidemia, hypertension, CAD, CCI-R scores, urbanization level of residence, and level of medical care, the adjusted HR (aHR) was 0.843 (95% CI 0.517–1.394, \( P = 0.243 \)). Furthermore, male gender, and patients in medical center were associated with a higher risk of incident diagnosis of OSA; the aHR were 1.86 (95% CI 1.223–2.828, \( P = 0.004 \)) and 3.007 (95% CI 1.509–6.277, \( P = 0.002 \)), respectively. In addition, patients aged ≥ 65 and CCI-R score of 1 were associated with a lower risk of OSA with the aHR as 0.208 (95% CI 0.062–0.696; \( P = 0.011 \)) and 0.692 (95% CI 0.297–0.996; \( P = 0.044 \)), respectively.

Effects of atomoxetine/oxybutynin use on the risk of obstructive sleep apnea. Table 3 presents 4 models of different ways of medication use. The incidence rates of OSA diagnosis in the exposed (either one or combination use of atomoxetine and oxybutynin) (\( N = 8940 \)) and the unexposed cohort (\( N = 26,820 \)), were 21.92 and 22.93 per 100,000 person-years, with the aHR as 0.846 (95% CI 0.517–1.394; \( P = 0.243 \)) when unexposed participants were taken as reference. The aHR of either one or AOC with the treatment duration of ≥ 366 days was 0.401 (95% CI 0.222–0.997; \( P = 0.049 \)). Furthermore, the aHR of oxybutynin use only and AOC with a combination use of atomoxetine and oxybutynin) (\( N = 8940 \)) and the unexposed cohort (\( N = 26,820 \)), were 21.92 and 22.93 per 100,000 person-years, with the aHR as 0.208 (95% CI 0.062–0.696; \( P = 0.011 \)) and 0.692 (95% CI 0.297–0.996; \( P = 0.044 \)), respectively.

Discussion

We used a population-based, retrospective cohort study designed with a large sample size and long-term follow-up duration to demonstrate that patients using either oxybutynin or AOC for more than 365 days were associated with a decreased risk of an incident diagnosis of OSA.

In this study, we have examined the association of the use of atomoxetine and oxybutynin with the risk of an incident diagnosis of OSA. After adjusting covariates, the aHR was 0.846 (95% CI 0.517–1.394, \( P = 0.243 \)) in the exposed cohort, when compared with the unexposed cohort. In other words, no significant difference was observed in the risk of an incident diagnosis of OSA between these two groups. However, patients with either oxybutynin or AOC use for more than 365 days had decreased risk of incident diagnosis of OSA, with aHR of 0.307 (95% CI 0.102–0.933, \( P = 0.002 \)) and 0.299 (95% CI 0.102–0.933, \( P = 0.002 \)), respectively.

The findings of this study found that the use of AOC may reduce the incidence of OSA based on a very preliminary clinical work, which suggests that one-night use of AOC resulted in a ≥ 50% reduction of AHI in OSA patients, but neither atomoxetine nor oxybutynin reduced the AHI when administered alone\textsuperscript{16}. In comparison to the previous trial\textsuperscript{16}, this study was a retrospective cohort study involving a large nationwide database to present real-world data; the previous study was a pilot clinical trial with a small sample size. In addition, we found a protective effect in terms of reducing the risk of an incident diagnosis of OSA with long-term AOC use (≥ 366 days). The results indicated that AOC use for ≥ 365 days might benefit upper airway function during sleep and reduce the risk of OSA. Finally, our study found that long-term use (≥ 366 days) of oxybutynin, but not atomoxetine, had borderline significance (\( P = 0.045 \)) in reducing the risk of an incident diagnosis of OSA. Although the previous clinical study did not find significant benefits with the use of oxybutynin alone\textsuperscript{16}, our study provides some insight into the role of oxybutynin in OSA.
| Variables                  | Exposed cohort* | Unexposed cohort | P   |
|---------------------------|-----------------|------------------|-----|
| n                         | %               | n                | %   |
| Total                     | 8940            | 25.00            | 26,820 | 75.00 |
| Sex                       |                 |                  | 0.999 |
| Male                      | 5068            | 56.69            | 15,204 | 56.69 |
| Female                    | 3872            | 43.31            | 11,616 | 43.31 |
| Age (years)               | 62.36 ± 18.55   | 60.97 ± 18.72    | 0.149 |
| Age group (years)         |                 |                  | 0.999 |
| 0–12                      | 244             | 2.73             | 732   | 2.73  |
| 13–17                     | 120             | 1.34             | 360   | 1.34  |
| 18–44                     | 1093            | 12.23            | 3279  | 12.23 |
| 45–64                     | 2349            | 26.28            | 7047  | 26.28 |
| ≥ 65                      | 5134            | 57.43            | 15,402 | 57.43 |
| Marital status            |                 |                  | 0.540 |
| Without                   | 4875            | 54.53            | 14,725 | 54.90 |
| With                      | 4065            | 45.47            | 12,095 | 45.10 |
| Educational years         |                 |                  | 0.699 |
| ≥12                       | 4972            | 55.62            | 14,979 | 55.85 |
| ≥12                       | 3968            | 44.38            | 11,841 | 44.15 |
| Insured premium (NT$)     |                 |                  | 0.001 |
| < 18,000                  | 8808            | 98.52            | 26,548 | 98.99 |
| 18,000–34,999             | 115             | 1.29             | 224   | 0.84  |
| ≥ 35,000                  | 17              | 0.19             | 48    | 0.18  |
| ADHD                      | 851             | 9.52             | 277   | 1.03  | < 0.001 |
| OAB                       | 890             | 9.96             | 270   | 1.01  | < 0.001 |
| DM                        | 1826            | 20.43            | 3740  | 13.94 | < 0.001 |
| Hyperlipidemia            | 112             | 1.25             | 741   | 2.76  | < 0.001 |
| Hypertension              | 1812            | 20.27            | 4796  | 17.88 | < 0.001 |
| CAD                       | 526             | 5.88             | 2374  | 8.85  | < 0.001 |
| CCI_R                     |                 |                  | < 0.001 |
| 0                         | 5905            | 66.05            | 16,766 | 62.51 |
| 1                         | 1252            | 14.00            | 5259  | 19.61 |
| 2                         | 586             | 6.55             | 1831  | 6.83  |
| 3                         | 786             | 8.79             | 1652  | 6.16  |
| ≥ 4                       | 411             | 4.60             | 1312  | 4.89  |
| Location                  |                 |                  | < 0.001 |
| Northern Taiwan           | 3788            | 42.37            | 10,533 | 39.27 |
| Middle Taiwan             | 2317            | 25.92            | 7400  | 27.59 |
| Southern Taiwan           | 2197            | 24.57            | 7037  | 26.24 |
| Eastern Taiwan            | 612             | 6.85             | 1699  | 6.33  |
| Outer islands             | 26              | 0.29             | 151   | 0.56  |
| Urbanization level        |                 |                  | < 0.001 |
| 1 (The highest)           | 3192            | 35.70            | 8901  | 33.19 |
| 2                         | 3864            | 43.22            | 11,492 | 42.85 |
| 3                         | 599             | 6.70             | 1894  | 7.06  |
| 4 (the lowest)            | 1285            | 14.37            | 4533  | 16.90 |
| Level of medical care     |                 |                  | < 0.001 |
| Medical center            | 3667            | 41.02            | 8457  | 31.53 |
| Regional hospital         | 3928            | 43.94            | 8378  | 31.24 |
| Local hospital            | 1345            | 15.04            | 9985  | 37.23 |

Table 1. Characteristics of study at the baseline. P: Chi-square/Fisher exact test on categorical variables and t-test on continue variables; ADHD: attention deficit hyperactivity disorder; OAB: overactive bladder; DM: diabetes mellitus; CAD: coronary artery disease; CCI_R: Charlson Comorbidity Index, revised. *Exposed cohort: subjects exposed to atomoxetine or oxybutynin during the study period.
In addition, Table 2 shows that patients aged ≥ 65 were associated with a lower risk of OSA. However, some studies have demonstrated that the prevalence of OSA is higher in elderly patients. There are several reasons for this phenomenon. First, some of our patients were prescribed atomoxetine or oxybutynin, and the use of such medications may influence the occurrence of OSA. Second, the home sleep test was not included in the National Health Insurance (NHI) in Taiwan. Besides, it is not convenient for the elderly to perform overnight polysomnography in hospitals. These reasons might lead to a lower OSA diagnostic rate in the elderly in Taiwan.

Furthermore, Table 3 shows that the prevalence of OSA in the exposed and unexposed cohorts was 0.28% and 0.29%, respectively. The prevalence of OSA in our study was lower than that reported in other studies. This finding can be explained by the following reasons. First, the home sleep test is not popular in Taiwan, and it decreases the willingness for patients to undergo OSA evaluation. Second, we used strict criteria for OSA

| Variables                      | Crude HR | 95% CI | P     | aHR   | 95% CI | P     |
|--------------------------------|----------|--------|-------|-------|--------|-------|
| **Atomoxetine/oxybutynin**     |          |        |       |       |        |       |
| No use                         | Reference|        |       | Reference|       |       |
| Either monotherapy or AOC      | 0.896    | 0.681  | 1.323 | 0.242 | 0.846  | 0.517 | 1.934 | 0.243 |
| **Gender**                     |          |        |       |       |        |       |
| Male                           | 1.771    | 1.166  | 2.688 | 0.007 | 1.860  | 1.223 | 2.828 | 0.004 |
| Female                         | Reference|        |       | Reference|       |       |
| **Age (years)**                |          |        |       |       |        |       |
| 0–12                           | Reference|        |       | Reference|       |       |
| 13–17                          | 0.000    | –      | –     | 0.947 | 0.000  | –     | –     | 0.963 |
| 18–44                          | 0.479    | 0.141  | 1.627 | 0.238 | 0.649  | 0.191 | 2.213 | 0.490 |
| 45–64                          | 0.286    | 0.088  | 0.956 | 0.042 | 0.421  | 0.124 | 1.428 | 0.165 |
| ≥65                            | 0.183    | 0.041  | 0.432 | 0.001 | 0.208  | 0.062 | 0.696 | 0.011 |
| **Marital status**             |          |        |       |       |        |       |
| Without                        | 1.382    | 0.811  | 1.970 | 0.787 | 1.562  | 0.852 | 2.030 | 0.897 |
| **Educational years**          |          |        |       |       |        |       |
| ≥12                            | 1.301    | 0.705  | 1.744 | 0.652 | 1.453  | 0.776 | 1.986 | 0.742 |
| **Insured premium (NT$)**      |          |        |       |       |        |       |
| <18,000                        | Reference|        |       | Reference|       |       |
| 18,000–34,999                  | 0.712    | 0.099  | 5.105 | 0.735 | 0.681  | 0.095 | 4.888 | 0.702 |
| ≥35,000                        | 0.000    | –      | –     | 0.963 | 0.000  | –     | –     | 0.977 |
| ADHD                           | 0.000    | –      | –     | 0.997 | 0.000  | –     | –     | 0.993 |
| OAB                            | 0.000    | –      | –     | 0.997 | 0.000  | –     | –     | 0.995 |
| DM                             | 0.797    | 0.479  | 1.326 | 0.383 | 0.946  | 0.558 | 1.604 | 0.837 |
| Hyperlipidemia                 | 1.240    | 0.456  | 3.374 | 0.673 | 1.390  | 0.500 | 3.865 | 0.527 |
| Hypertension                   | 0.793    | 0.507  | 1.399 | 0.308 | 0.891  | 0.555 | 1.430 | 0.631 |
| CAD                            | 0.172    | 0.042  | 0.698 | 0.014 | 0.160  | 0.039 | 1.057 | 0.061 |
| **CCI_R**                      |          |        |       |       |        |       |
| 0                              | Reference|        |       | Reference|       |       |
| 1                              | 0.946    | 0.743  | 1.176 | 0.092 | 0.692  | 0.297 | 0.996 | 0.044 |
| 2                              | 1.087    | 0.304  | 1.453 | 0.306 | 1.097  | 0.345 | 1.533 | 0.265 |
| 3                              | 1.369    | 0.116  | 1.765 | 0.533 | 1.264  | 0.567 | 2.005 | 0.397 |
| ≥4                             | 1.664    | 0.012  | 3.930 | 0.211 | 1.857  | 0.735 | 3.798 | 0.184 |
| **Urbanization level**         |          |        |       |       |        |       |
| 1 (the highest)                | 2.574    | 1.287  | 5.147 | 0.008 | 1.522  | 0.707 | 3.277 | 0.283 |
| 2                              | 1.847    | 0.935  | 3.651 | 0.077 | 1.326  | 0.645 | 2.730 | 0.443 |
| 3                              | 1.232    | 0.421  | 3.606 | 0.703 | 1.099  | 0.375 | 3.221 | 0.863 |
| 4 (the lowest)                 | Reference|        |       | Reference|       |       |
| **Level of medical care**      |          |        |       |       |        |       |
| Hospital center                | 3.361    | 1.753  | 6.442 | <0.001 | 3.007  | 1.509 | 6.277 | 0.002 |
| Regional hospital              | 1.765    | 0.906  | 3.442 | 0.095 | 1.680  | 0.852 | 3.312 | 0.134 |
| Local hospital                 | Reference|        |       | Reference|       |       |

Table 2. Cox regression analysis of factors contributing to obstructive sleep apnea. Location not included given collinearity with urbanization level. aHR: adjusted Hazard ratio (adjusted for the variables listed in Table 1), AOC: atomoxetine-oxybutynin combination; CI: confidence interval; ADHD: attention deficit hyperactivity disorder; OAB: overactive bladder; DM: diabetes mellitus; CAD: coronary artery disease; CCI_R: Charlson Comorbidity Index, revised.
enrollment in our study, in which each enrolled patient with a diagnosis of OSA was required to have a poly-
osomnography examination record from the database within one year before or after the OSA occurred during
the study period. This enrollment strategy might have contributed to the lower prevalence of OSA in this study.
Moreover, a low prevalence rate and underdiagnosed OSA have also been reported in other Asian  countries21,22.
It is necessary to highlight the importance of OSA in the general population and among clinicians in Asia.

Possible mechanisms for the decreased risk of OSA in response to long-term AOC use. The mechanisms underlying the association between the long-term use of oxybutynin and AOC and the reduced risk of an incident diagnosis of OSA are still unclear. However, several possible mechanisms may explain the results. The research group that conducted a previous pilot study on AOC use and the change in OSA severity further investigated the possible effects of atomoxetine and oxybutynin on the respiratory tract23. Atomoxetine is a selective norepinephrine reuptake inhibitor that is used in patients with attention-deficit hyperactivity disorder. Its effect of increasing the level of norepinephrine during sleep could stimulate the motoneurons of the upper air-
way and reduce airway collapsibility24–26. In a recent study, atomoxetine alone significantly reduced the arousal
threshold and stability of ventilatory control and improved collapsibility, but not muscle compensation during
spontaneous breathing while sleeping23. Oxybutynin is an antimuscarinic agent frequently used for overactive
bladder. The antimuscarinic receptor M2 is one of the few receptors expressed in both the premotor and motor
areas of the hypoglossal motor nucleus, and it influences the genioglossus muscle of the tongue27,28. In a recent
study, compared with placebo, oxybutynin alone improved collapsibility but not muscle compensation during
spontaneous breathing while sleeping23. The concurrent use of atomoxetine and oxybutynin might enhance
upper airway muscle activity and reduce the incidence of OSA.

We should also mention the possible side effects of atomoxetine and oxybutynin if these medications are
considered for a long-term use. In general, atomoxetine is relatively safe for patients with ADHD. However,
safety in patients without ADHD is not clear, and the use of atomoxetine may increase blood pressure and
heart rate29. Oxybutynin is an antimuscarinic agent that might cause significant cognitive deterioration even in
short-term use. Although AOC may have a certain value for the development of OSA, the side effects of these
medications should be closely monitored.

Limitations. This study has several limitations. First, the diagnosis of OSA was obtained based on the ICD-
9-CM codes of OSA and record of doing a polysomnography exam within one year before or after OSA diag-
nostic code instead of the polysomnography reports. These data may not be accurate enough for outcome meas-
urement. Furthermore, the severity of OSA and data of body mass index could not be examined in our study.
However, the National Health Insurance Administration in Taiwan has made every effort to verify the exactness
of the diagnoses in the database. Additionally, to further ensure accuracy, we used the previously published
method with an accuracy rate of 87% to define the OSA cases30. Second, the use of atomoxetine and oxybutynin
was assessed based on prescription records, but the actual dosage used, time of use, and rate of refills were

| Model | Atomoxetine/oxybutynin use | Population | Events | PYs | Rate (per 10^5 PYs) | aHR | 95% CI | P |
|-------|---------------------------|------------|--------|-----|---------------------|-----|--------|---|
| 1     | No use                    | 26,820     | 78     | 340,161.37     | 22.93 | Reference |
|       | Either monotherapy or AOC | 8940       | 25     | 114,053.98     | 21.92 | 0.846 | 0.517 | 1.934 | 0.243 |
| 2     | No use                    | 26,820     | 78     | 340,161.37     | 22.93 | Reference |
|       | Atomoxetine only          | 4301       | 13     | 48,121.81      | 27.01 | 1.264 | 0.862 | 2.894 | 0.392 |
|       | Oxybutynin only           | 4502       | 10     | 53,454.01      | 18.71 | 0.782 | 0.503 | 1.880 | 0.241 |
|       | AOC                       | 137        | 2      | 12,478.16      | 16.03 | 0.466 | 0.264 | 1.307 | 0.181 |
| 3     | No use                    | 26,820     | 78     | 340,161.37     | 22.93 | Reference |
|       | Either monotherapy or AOC, 30–365 days | 2,75  | 16   | 47,505.07      | 33.68 | 1.463 | 0.672 | 2.565 | 0.711 |
|       | Either monotherapy or AOC, ≥ 366 days | 5965 | 9    | 66,548.91      | 13.52 | 0.401 | 0.222 | 0.997 | 0.049 |
| 4     | No use                    | 26,820     | 78     | 340,161.37     | 22.93 | Reference |
|       | Atomoxetine only, 30–365 days | 1312 | 9    | 21,101.78      | 42.65 | 2.067 | 0.975 | 4.121 | 0.896 |
|       | Atomoxetine only, ≥ 366 days | 2989 | 4    | 27,020.03      | 14.80 | 0.438 | 0.330 | 1.996 | 0.245 |
|       | Oxybutynin only, 30–365 days | 1583 | 6    | 21,981.04      | 27.30 | 1.385 | 0.904 | 2.670 | 0.332 |
|       | Oxybutynin only, ≥ 366 days | 2919 | 4    | 31,472.97      | 12.71 | 0.307 | 0.204 | 0.995 | 0.045 |
|       | AOC, 30–365 days          | 809       | 1     | 422.25         | 22.61 | 1.154 | 0.892 | 1.501 | 0.197 |
|       | AOC, ≥ 366 days           | 57        | 1     | 8055.91        | 12.41 | 0.299 | 0.102 | 0.933 | 0.002 |

Table 3. Effects of atomoxetine/oxybutynin use on the risk of obstructive sleep apnea. PYs: person-years; aHR: adjusted Hazard ratio (adjusted for the variables listed in Table 1), CI: confidence interval; AOC: atomoxetine-oxybutynin combination.
unknown. However, we compared the different durations of medication prescription to minimize the impact of this limitation. Third, the reasons for taking atomoxetine-oxybutynin were not for OSA. Thus, the cases and controls differ in some ways that may bias the results which cannot be fully accounted for in the analyses. However, we included several important covariates like DM, CAD, hypertension to minimize the impacts. Fourth, several important unmeasured confounding factors that may have affected the results. For example, body mass index, smoking habit, and alcohol consumption are related to the incidence of OSA and those factors cannot be assessed by the National Health Insurance Research Database (NHIRD). Since the use of atomoxetine and oxybutynin for treating OSA is a novel and important issue, the results of this nationwide population-based, retrospective cohort study is still important. Finally, the actual mechanisms related to the association between the use of atomoxetine and oxybutynin and OSA risk are still not clear. Though we provided some possible mechanisms in the discussion, further investigation is warranted to shed more light on this issue.

In conclusion, this study provides evidence that long-term (≥ 366 days) atomoxetine-oxybutynin combination use may not increase the risk of OSA, but may be beneficial for its prevention.

Methods

Data sources. The NHI program was launched in Taiwan in 1995, and as of June 2009, including contracts with 97% of the medical providers with approximately 23 million beneficiaries, or more than 99% of the entire population54,55. The NHIRD, which contains all the claims data of the beneficiaries, uses the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes to record the diagnoses56. The details of the program have been documented in previous studies54–56.

A subset of NHIRD, the Longitudinal Health Insurance Database (LHID) of two million randomized, sampled individuals between the years 2000 and 2015, was used to study the association between atomoxetine or oxybutynin and the risk of an incident diagnosis of OSA. The present study used the NHIRD to identify patients with the use of atomoxetine and oxybutynin.

Ethical statement. This study was approved by the Institutional Review Board of the Tri-Service General Hospital and waived the need for written informed consent (IRB No. B-109-21). All research methods were carried out following the relevant guidelines and regulations.

Study design and sampled participants. This study used a population-based, matched-cohort design. Patients who had used atomoxetine or oxybutynin for at least 30 days were enrolled from the LHID between January 1, 2000 and December 31, 2015. The exclusion criteria were as follows: (1) participants who had used atomoxetine or oxybutynin before the cohort entry date, (2) participants who had used atomoxetine or oxybutynin for less than 30 days, (3) patients diagnosed with OSA before the cohort entry date, (4) patients diagnosed with OSA before the prescription of atomoxetine or oxybutynin, (5) patients diagnosed with narcolepsy, ICD-9-CM code 347, and (6) missing data. The cohort entry date was defined as the first prescription date of atomoxetine or oxybutynin during the study period. The exposed and unexposed to atomoxetine or oxybutynin groups were selected in a ratio of 1:3 with sex, age, and index year matching. They were followed until the development of OSA, withdrawal from the NHI program, or till the end of the study.

Major outcomes. The study outcome was the incident diagnosis of OSA, which was defined as patients diagnosed with one of the following ICD-9-CM codes: 327.23, 780.51, 780.53, and 780.57. Each enrolled case with a diagnosis of OSA was required to have a polysomnography exam record from the database within one year before or after OSA occurred during the study period, regarding one previous study44. The accuracy of the diagnosis of OSA with the above enrollment has been validated as 87%50. The date of the first prescription of atomoxetine or oxybutynin was defined as the index date for the patient.

Covariates. The covariates included sex, age groups (0–12, 13–17, 18–44, 45–64, ≥ 65 years), marital status, educational years (< 12 years and ≥ 12 years), monthly income (in New Taiwan Dollars [NT$]; < 18,000, 18,000–34,999, ≥ 35,000), geographical area of residence (north, center, south, and east of Taiwan), urbanization level of residence (levels 1 to 4), and level of medical care. In the urbanization level of residence was defined according to the population and various indicators of the level of development. Level 1 was defined as a population of > 1,250,000, and a specific designation as political, economic, cultural, and metropolitan development. Level 2 was defined as a population between 500,000 and 1,249,999, and as playing an important role in politics, economy, and culture. Urbanization levels 3 and 4 were defined as a population between 500,000 and 1,249,999, and as playing an important role in politics, economy, and culture. The covariates were referenced with previous articles related to studies of sleep-related topics by using the NHIRD54–56.

Comorbidity. We included the following comorbidities in the analysis: ADHD (ICD-9-CM: 314), OAB (ICD-9-CM: 596.51), DM (ICD-9-CM: 250), hyperlipidemia (ICD-9-CM: 272.x), hypertension (ICD-9-CM: 401.1, 401.9, 402.10, 402.90, 404.10, 404.90, 405.1, 405.9), and CAD (ICD-9-CM: 411, 413, 414). Moreover, we also used the Charlson Comorbidity Index (CCI, scored 0, 1, 2, 3, ≥ 4), which categorizes the comorbidities using the ICD-9-CM codes, scores each comorbidity category, and combines all the scores to calculate a single comorbidity score. A score of zero indicates that no comorbidities were found, and higher scores indicate higher comorbidity burdens46–48. We removed the items of DM, hypertension, and CAD from the items of CCI, and renamed it as CCI_R, to prevent the multicollinearity with other comorbidities. Figure 1 presents a detailed flowchart regarding participant selection and the study design.
Statistical analysis. All statistical analyses were performed using SPSS for Windows, version 22.0 (IBM Corp., Armonk, NY). We used χ² and t-tests to evaluate the distributions of the categorical and continuous variables, respectively, with the Fischer exact examination. The multivariate Cox proportional hazards regression analysis was used to determine the risk of an incident diagnosis of OSA, and the results are presented using hazard ratio (HR) with 95% confidence interval (CI). We adjusted for the following potential confounders: sex, age, marital status, educational years, monthly income, ADHD, OAB, DM, hyperlipidemia, hypertension, CAD, CCI_R scores, urbanization level of the residence, and level of care. According to the multicollinearity between the geographical area and urbanization level of the residence, we chose the urbanization level of the residence for adjustment. The difference in the risk of an incident diagnosis of OSA between the exposed cohort and unexposed cohort was estimated using the Kaplan–Meier method with the log-rank test. We further categorized drug use as short-term (30–365 days) and long-term (≥ 366 days) use before the index date. Four different models were used for different patterns of atomoxetine/oxybutynin use in the determination of the association with an incident diagnosis of OSA. Model 1 investigated the difference between no use and either monotherapy or AOC. Model 2 further divided the groups into no use, atomoxetine use only, oxybutynin use only, and the use of AOC. Model 3 incorporated the duration of medication use and divided the groups into no use, either monotherapy or AOC for 30–365 days, and ≥ 366 days. Model 4 investigated the duration of each medication used with the groups as no use, atomoxetine use only for 30–365 days, and ≥ 366 days, oxybutynin use only for 30–365 days and ≥ 366 days, and AOC therapy for 30–365 days and ≥ 366 days. A 2-tailed p-value of < 0.05 indicated statistical significance.

Received: 5 July 2020; Accepted: 7 May 2021
Published online: 15 June 2021
References

1. Patil, S. P., Schneider, H., Schwartz, A. R. & Smith, P. L. Adult obstructive sleep apnea: pathophysiology and diagnosis. *Chest* **132**, 325–337 (2007).

2. Eckert, D. I., White, D. P., Jordan, A. S., Malhotra, A. & Wellman, A. Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. *Am. J. Respir. Crit. Care Med.* **188**, 996–1004 (2013).

3. George, C. F. Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP. *Thorax* **56**, 508–512 (2001).

4. Peker, Y., Hedner, J., Norum, J., Kraiczi, H. & Carlson, J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. *Am. J. Respir. Crit. Care Med.* **166**, 159–165 (2002).

5. Bassetti, C. L., Milanova, M. & Gugger, M. Sleep-disordered breathing and acute ischemic stroke: diagnosis, risk factors, treatment, evolution, and long-term clinical outcome. *Stroke* **37**, 967–972 (2006).

6. Shahar, E. et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. *Am. J. Respir. Crit. Care Med.* **163**, 19–25 (2001).

7. Nachtman, A., Stang, A., Wang, Y. M., Wondzinski, E. & Thilmann, A. F. Association of obstructive sleep apnea and stenotic artery disease in ischemic stroke patients. *Atherosclerosis* **169**, 301–307 (2003).

8. Jean-Louis, G., Zizi, F., Clark, L. T., Brown, C. D. & McFarlane, S. I. Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. *J. Clin. Sleep Med.* **4**, 261–272 (2008).

9. Veasey, S. C. & Rosen, J. M. Obstructive sleep apnea in adults. *N. Engl. J. Med.* **380**, 1442–1449 (2019).

10. Kalkar, R. K. & Berry, R. B. Positive airway pressure treatment for obstructive sleep apnea. *Chest* **132**, 1057–1072 (2007).

11. Sawyer, A. M. *et al.* A systematic review of CPAP adherence across age groups: clinical and empiric insights for developing CPAP adherence interventions. *Sleep Med. Rev.* **15**, 343–356 (2011).

12. Pliska, B. T., Nam, H., Lowe, A. A. & Almeida, F. R. Obstructive sleep apnea and mandibular advancement splints: occlusal effects and progression of changes associated with a decade of treatment. *J. Clin. Sleep Med.* **10**, 1285–1291 (2014).

13. Caples, S. M. *et al.* Surgical modifications of the upper airway for obstructive sleep apnea in adults: a systematic review and meta-analysis. *Sleep* **33**, 1396–1407 (2010).

14. Woodson, B. T. *et al.* Upper airway stimulation for obstructive sleep apnea: 5-year outcomes. *Otolaryngol. Head Neck Surg.* **159**, 194–202 (2018).

15. Ganil, T., Haile, S. R., Thiel, S., Osowski, M. & Kohler, M. Efficacy of pharmacotherapy for OSA in adults: a systematic review and network meta-analysis. *Sleep Med. Rev.* **46**, 74–86 (2019).

16. Taranto-Montemurro, L. *et al.* The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity: a randomized, placebo-controlled, double-blind crossover trial. *Am. J. Respir. Crit. Care Med.* **199**, 1267–1276 (2018).

17. Senaratna, C. V. *et al.* Prevalence of obstructive sleep apnea in the general population: a systematic review. *Sleep Med. Rev.* **34**, 70–81 (2017).

18. Fietze, L. *et al.* Prevalence and association analysis of obstructive sleep apnea with gender and age differences—results of SHIP-Trend. *J. Sleep Res.* **28**, e12770 (2019).

19. Villaneuva, A. T., Buchanan, P. R., Yee, B. J. & Grunstein, R. R. Ethnicity and obstructive sleep apnoea. *Sleep Med. Rev.* **9**, 419–436 (2005).

20. Hnin, K. *et al.* The impact of ethnicity on the prevalence and severity of obstructive sleep apnea. *Sleep Med. Rev.* **41**, 78–86 (2018).

21. Mirrakhimov, A. E., Sooronbaev, T. & Mirrakhimov, E. M. Prevalence of obstructive sleep apnea in Asian adults: a systematic review of the literature. *BMC Pulm. Med.* **13**, 10 (2013).

22. Loo, G. H., Rajan, R., Mohd Tamil, A. & Ritza Kosai, N. Prevalence of obstructive sleep apnea in an Asian bariatric population: an underdiagnosed dilemma. *Surg. Obes. Relat. Dis.* **16**, 778–783 (2020).

23. Taranto-Montemurro, L.* et al.* Effects of the combination of atomoxetine and oxybutynin on OSA endotypes traits. *Chest* **157**, 1626–1636 (2020).

24. Taranto-Montemurro, L. *et al.* Desipramine increases genioglossus activity and reduces upper airway collapsibility during non-REM sleep in healthy subjects. *Am. J. Respir. Crit. Care Med.* **194**, 878–885 (2016).

25. Taranto-Montemurro, L. *et al.* Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation. *Eur. Respir. J.* **48**, 1340–1350 (2016).

26. Fenik, V. R., Davies, R. O. & Kuhn, L. REM sleep-like atonia of hypoglossal (XII) motoneurons is caused by loss of noradrenergic and serotonergic inputs. *Am. J. Respir. Crit. Care Med.* **172**, 1322–1330 (2005).

27. Horner, R. L., Grace, K. P. & Wellman, A. A resource of potential drug targets and strategic decision-making for obstructive sleep apnoea pharmacotherapy. *Respirology* **22**, 861–873 (2017).

28. Liu, X., Sood, S., Liu, H. & Horner, R. L. Opposing muscarinic and nicotinic modulation of hypoglossal motor output to genioglossus muscle in rats in vivo. *J. Physiol.* **565**, 965–980 (2005).

29. Camporeale, A. *et al.* Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials. *J. Psychopharmacol.* **29**, 3–14 (2015).

30. Su, Y. Y. *et al.* Sleep apnea and risk of mortality from pulmonary: a nationwide population-based study. *CMAJ* **186**, 415–421 (2014).

31. Ho Chun, W. Taiwan’s healthcare report 2010. *EMJA* **1**, 563–585 (2010).

32. Needham, D. M., Scales, D. C., Laupacis, A. & Pronovost, P. J. A systematic review of the Charlson comorbidity index using Canadian administrative databases: a perspective on risk adjustment in critical care research. *J. Crit. Care* **20**, 12–19 (2005).

33. Chinese Hospital Association. *ICD-9-CM English Chinese Dictionary* (Chinese Hospital Association Press, New York, 2000).

34. Chien, W. C. *et al.* Is weight control surgery associated with increased risk of newly onset psychiatric disorders? A population-based, matched cohort study in Taiwan. *J. Med. Sci. 37*, 137–149 (2017).

35. Tzeng, N. S. *et al.* Is Zolpidem associated with increased risk of fractures in the elderly with sleep disorders? A nationwide case cross-over study in Taiwan. *PloS ONE 10*, e0146035 (2015).

36. Chen, T. Y. *et al.* The use of benzodiazepine receptor agonists and the risk of hospitalization for pneumonia: a nationwide population-based nested case-control study. *Chest* **153**, 161–171 (2018).

37. Tzeng, N. S. *et al.* Increased risk of psychiatric disorders in allergic diseases: a nationwide, population-based, Cohort Study. *Front. Psych.* **9**, 133 (2018).

38. Tzeng, N. S. *et al.* Risk of psychiatric disorders in overactive bladder syndrome: a nationwide cohort study in Taiwan. *J Investig. Med.* **67**, 312–318 (2019).

39. Tzeng, N. S. *et al.* Risk of psychiatric disorders in Guillain-Barre syndrome: a nationwide, population-based, cohort study. *J. Neurol. Sci.* **381**, 88–94 (2017).

40. Xing, Y. J. *et al.* Risk of erectile dysfunction after traumatic brain injury: a nationwide population-based cohort study in Taiwan. *Am. J. Mens. Health* **12**, 913–925 (2018).

41. Yeh, H. W., Chien, W. C., Chung, C. H., Hu, J. M. & Tzeng, N. S. Risk of psychiatric disorders in irritable bowel syndrome - A nationwide, population-based, cohort study. *Int. J. Clin. Pract.* **72**, e13212 (2018).

42. Tzeng, N. S. *et al.* The risk of hospitalization for motor vehicle accident injury in narcolepsy and the benefits of stimulant use: a nationwide cohort study in Taiwan. *J. Clin. Sleep Med.* **15**, 881–889 (2019).

43. Hsieh, C. Y. *et al.* Taiwan’s National Health Insurance Research Database: past and future. *Clin. Epidemiol.* **11**, 349–358 (2019).
44. Shiao, T. H. et al. Sleep apnea and risk of peptic ulcer bleeding: a nationwide population-based study. *Am. J. Med.* **126**, 249–255, e241 (2013).
45. Chen, T. Y. et al. Sex and age differences in the association between anxiety disorders and narcolepsy: a nationwide population-based case control study. *J. Affect Disord.* **264**, 130–137 (2020).
46. Willison, H. J., Jacobs, B. C. & van Doorn, P. A. Guillain-Barre syndrome: surveillance and cost of treatment strategies—authors’ reply. *Lancet* **389**, 253–254 (2017).
47. Group, S. G.-B. S. T. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. *Plasma Exchange. Lancet.* **349**, 225–230 (1997).
48. Wong, A. H. Y. et al. The value of comparing mortality of Guillain-Barré syndrome across different regions. *J. Neuro Sci.* **44**, 60–62 (2014).

**Acknowledgements**

This work was supported by the Tri-Service General Hospital Research Foundation (TSGH-C107-106, TSGH-C108-003, TSGH-C108-151, TSGH-B-109010, TSGH-D-109197, TSGH-D-110176, TSGH-E-110240, and TSGH-B-110012), the Taoyuan Armed Forces General Hospital (TYAFGH-A-110020), and the Medical Affairs Bureau, Ministry of Defense of Taiwan (MAB-107-084 and MND-MAB-110-087). The authors would like to thank Dr. Cheng-Yi Wang for preparing this manuscript. This study is based, in part, on data from the National Health Insurance Research Database provided by the Health and Welfare Data Science Center (HWDC), Ministry of Health and Welfare (MOHW). The interpretation and conclusions contained in this article do not represent those of the HWDC, MOHW.

**Author contributions**

T.Y.C. contributed to the study design and wrote the manuscript; C.H.C. contributed to the statistical analysis; H.A.C., Y.C.K., S.Y.C., T.B.J.K., and C.C.H.Y. contributed to manuscript preparation and editing; W.C.C. and N.S.T. contributed to the study design, statistical analysis, supervision of the work, and manuscript preparation.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Correspondence and requests for materials should be addressed to W.-C.C. or N.-S.T.

Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021